Autoimmune Diseases

Autoimmune Diseases / 2012 / Article
Special Issue

Systemic Lupus Erythematosus

View this Special Issue

Review Article | Open Access

Volume 2012 |Article ID 725249 | 7 pages | https://doi.org/10.1155/2012/725249

Osteonecrosis in Systemic Lupus Erythematosus: An Early, Frequent, and Not Always Symptomatic Complication

Academic Editor: Hiroshi Okamoto
Received16 May 2012
Accepted16 Jun 2012
Published05 Aug 2012

Abstract

Osteonecrosis may complicate the course of systemic lupus erythematosus and may contemporaneously affect multiple joints. The major risk factor associated with the development of osteonecrosis is the use of glucocorticoid at high doses. Recent studies using serial MRI, which represents the “gold standard” for the early detection of osteonecrosis, yielded some interesting findings about the natural history of this clinical entity. Osteonecrosis in the majority of the cases is asymptomatic and occurs early in the course of the disease. Its later occurrence is associated with lupus flare that requires the increase of corticosteroid dose. The optimal treatment of osteonecrosis is controversial. In case of silent osteonecrosis involving a small area conservative strategy is usually adequate. When lesions are symptomatic surgical treatment as core decompression or free vascularized fibular grafting is required; extracorporeal shockwave treatment may represent an alternative therapeutic approach. When the lesion has a medium-large dimension or involves a weight-bearing area bone collapse is a common complication requiring total joint replacement. Coadministration of bisphosphonate or warfarin with high doses of corticosteroid might be a promising preventive strategy of osteonecrosis.

1. Introduction

Osteonecrosis is a clinical entity characterized by death of bone marrow and trabecular bone as a result of a compromised artery supply. It may follow a trauma resulting in the displacement of a bone fragment that disrupts blood supply causing bone ischemia (posttraumatic osteonecrosis) or may complicate the course of many systemic diseases or conditions (atraumatic osteonecrosis). In a proportion of osteonecrosis a triggering event cannot be identified (idiopathic forms).

Osteonecrosis mainly affects long-bone epiphyses, in particular femoral head and condyles, distal end of the tibia, and humeral head and often shows a multifocal distribution. Systemic conditions known as risk factors for osteonecrosis are corticosteroid treatment, Cushing syndrome, organ transplant, systemic lupus erythematosus (SLE), antiphospholipid antibody syndrome, thrombophilia, alcoholism, dyslipidemia, Caisson disease, sickle cell disease, Gaucher disease, HIV infection, pancreatitis, inflammatory bowel diseases, and pregnancy [1, 2].

Osteonecrosis may be silent or may clinically present with a gradual onset characterized by mild or vague pain that may worsen after ambulation and subsequently progress to severe pain when bone collapse occurs; in other cases osteonecrosis may cause a sudden onset deep joint pain that initially is elicited by movement and later is present also at rest.

Osteonecrosis may be asymptomatic and not progressive when a small fragment of bone tissue is involved. In case of medium-large bone area involvement usually the lesion progresses and eventually the necrotic tissue collapses. The clinical implication is a severe joint damage requiring arthroplasty. Negative prognostic factor is also the involvement of a weight-bearing area, such as the femoral head.

During the recent years magnetic resonance imaging (MRI) has become the “gold standard” technique for the early recognition of osteonecrosis considering the high sensitivity and specificity; it may detect early stage, silent osteonecrotic lesions, which are not diagnosed by both plain radiography and bone scan. Osteonecrosis is defined by MRI image of low-intensity band (band-like pattern) on T1-weighted images [3] which is attributed to the reaction at the interface between dead and normal bone.

In SLE the prevalence of symptomatic lesions in studies carried when MRI was not available varied from 2.1 to 30% [416]. More recent MRI studies allowed the diagnosis of osteonecrotic lesions in higher percentage of the patients. By serial MRI evaluation of hips and knees in 72 SLE patients on high doses of corticosteroid therapy osteonecrosis was observed in 32 subjects (44%), with a multifocal distribution in the majority of the cases. Thus 92 joints had osteonecrosis features, with a slightly predominance of knee involvement [17]. In all cases the bone lesions were asymptomatic at the time of the diagnosis and during the one year followup.

Osteonecrosis often involves more than one skeletal site; a case of SLE with twelve simultaneous osteonecrotic lesions was reported [18]; long-bone epiphyses are usually involved, but flat bones as ilium, sternum, talus, and vertebral bodies may be affected too [10, 19]. When osteonecrosis at one skeletal site is found in a SLE patient, a screening for other concomitant lesions is generally recommended since multifocal involvement is not infrequent.

Symptomatic osteonecrosis does not increase mortality but heavily impacts on quality of life and causes a significant physical disability as measured by the Health Assessment Questionnaire [16].

Progression from clinically occult osteonecrosis detected by MRI to symptomatic lesions is not frequent [10, 20]. A review about the natural history of asymptomatic osteonecrosis of femoral head showed that patients affected by SLE presented the most benign course, while in subjects suffering from sickle cell anemia the rate of progression to symptomatic disease and/or femoral head collapse was the highest [21].

Among a cohort of 500 SLE cases 19 patients had undergone at least one total joint replacement. In most of these cases rheumatoid arthritis was associated to SLE [22].

2. Skeletal Manifestations in Systemic Lupus Erythematosus

SLE is a complex autoimmune disease that may involve any organ and apparatus; it is characterized by great heterogeneity and the clinical picture may vary considerably from patient to patient and in the same subject from the onset to the following course. The involvement of the bone tissue includes osteoporosis and osteonecrosis, both unrelated to the autoimmune pathophysiology of the disease. The etiology of osteoporosis is multifactorial: corticosteroid treatment, limited physical activity and premature ovarian failure favoured also by cyclophosphamide treatment courses may contribute to bone loss [23]; chronic systemic inflammation per se may favour bone loss through increased production of TNF, a cytokine that influences osteoclast maturation and activity [24]. High levels of oxidized LDLs promote the activation of both T cells and the transcription factor peroxisome proliferator-activated receptor (PPAR)γ2 [25], a key regulator of both osteoblast and adipocyte differentiation from mesenchymal stem cells, which reduces the osteoblast precursor number in favour of the adipocyte cell number [26]. SLE patients are invariably encouraged to avoid sunshine exposure and this increases the risk of vitamin D deficiency.

3. Pathogenetic Mechanisms That Lead to Atraumatic Osteonecrosis

Although the pathogenesis of nontraumatic osteonecrosis is not completely understood, it is known that many factors may induce bone ischemia and favour bone necrosis by intraluminal or extraluminal obliteration [1]. Intraluminal occlusion may be due to the release of nitrogen gas bubbles that impinge the blood vessels as occurs in acute decompression syndrome or Caisson disease or may be provoked by fat embolism, which is favoured by dyslipidemia and glucocorticoid treatment or by thrombosis. A thrombophilic status has been associated with osteonecrosis. In a study that evaluated 45 cases of osteonecrosis 82.2% and 46.7% of the patients showed at least one and two risk factors for thrombosis, respectively, in comparison with 30% and 2.5% of the controls [27]. It has also been reported that patients affected by osteonecrosis are more likely to have hypofibrinolytic 4G polymorphism of the plasminogen activator inhibitor-1 gene, methylenetetrahydrofolate reductase gene mutation with higher concentration of homocysteine, low protein S values, and high lipoprotein(a) levels than controls [28]. Sickle vasoocclusion in sickle cell anaemia is another mechanism which may lead to intraluminal obliteration causing both symptomatic and asymptomatic osteonecrosis, which frequently complicates the course of the disease, requiring joint replacement in many cases [29].

Extraluminal obliteration is due to bone marrow pressure elevation, which impairs intraosseous blood flow because of the bone inelasticity. This mechanism, first hypothesized in 1972 [30], may be due to glucocorticoid treatment and alcohol abuse that cause bone marrow adipocyte hypertrophy.

Chronic corticosteroid administration promotes fat conversion of red marrow, as demonstrated by a MRI study of the proximal femur in a cohort of premenopausal women affected by SLE. The magnitude of fat conversion paralleled the daily prednisolone intake and was more evident in patients who had had osteonecrosis. The increase of bone marrow fat content may elevate marrow pressure reducing arterial perfusion [31]. Other mechanisms leading to increase of marrow pressure are bone edema, bleeding or histiocyte proliferation, typical histologic feature of Gaucher disease. All these observations suggest that the so-called atraumatic osteonecrosis represents the final common pathway of many different conditions leading to impaired bone blood supply.

A nationwide epidemiologic survey performed in Japan in 2005 permitted to obtain clinical data from 1502 patients with atraumatic osteonecrosis of the femoral head. Systemic glucocorticoid therapy and alcoholism were the most frequent risk factors, being present in 51% and 31% of the cases, respectively. SLE represents the most frequent underlying disease in steroid-induced osteonecrosis (31.2% of the cases), followed by nephrotic syndrome (6.3% of the cases); polymyositis/dermatomyositis, thrombocytopenic purpura, bronchial asthma, and inflammatory eye diseases were the underlying illness in about 4% of the patients, whereas rheumatoid arthritis in less than 1%. These proportions clearly do not mirror the epidemiology of the diseases. The most common disorders requiring corticosteroid treatment are bronchial asthma and rheumatoid arthritis, where osteonecrosis is relatively rare. The high incidence of osteonecrosis in SLE, nephrotic syndrome, and other autoimmune diseases might be related to the higher corticosteroid doses used but also to the underlying disease [32].

In a large Japanese survey it was found that patients who receive glucocorticoid are at approximately 20-fold greater risk to develop osteonecrosis in comparison with nonusers [33]. Glucocorticoid administration was also found to be a significant risk factor for the rare atraumatic osteonecrosis of the distal radius and ulna [34].

In a recent large study on the incidence of osteonecrosis among patients requiring corticosteroid treatment it was reported that daily prednisone-equivalent dose > 40 mg/day in comparison with lower doses was associated with an OR of 4.2 to develop osteonecrosis [35]. It was also found that male sex was an additional risk factor for the development of the disease.

Besides the aforementioned effects of corticosteroids on fat content of bone marrow, these drugs may impair bone integrity by inducing apoptosis of osteoblasts and osteocytes [36] and through the downregulation of osteoprotegerin and the upregulation of RANKL impairing the balance between bone formation and bone resorption [37]. Even tough a genetic predisposition has never been reported, the association with some polymorphisms has been found. The multidrug resistance 3435 TT haplotype was found to be protective for the development of osteonecrosis both in SLE patients [38] and in renal transplant recipients [39]. Interestingly this haplotype is associated with a reduced intracellular concentration of corticosteroids.

4. Factors Associated with the Development of Osteonecrosis in Systemic Lupus Erythematosus

The use of corticosteroid therapy is the major risk factor for the development of osteonecrosis in SLE [4, 17, 4042].

The yearly incidence of osteonecrosis at hips and knees was prospectively investigated by MRI in a large cohort of patients requiring corticosteroid treatment for a variety of underlying diseases. MRI osteonecrosis (most often asymptomatic) developed in 255 (37%) of 687 joints evaluated in 173 SLE cases as compared with 107 (21%) of 512 joints in 129 non-SLE cases. The highest dose of corticosteroid was slightly different between SLE patients and subjects affected by other diseases (56.0 and 51.3 mg/day, resp.). The logistic regression analysis revealed that SLE patients had a higher risk to develop osteonecrosis versus other autoimmune or systemic diseases with an OR of 2.6. These results further confirm that SLE per se is a risk factor for osteonecrosis [35].

Vascular involvement, altered lipid metabolism, haemostatic abnormalities, and thrombophilia due to antiphospholipid antibodies have been considered as additional risk factors for the development of osteonecrosis in SLE. These conditions are generally reflecting a very high disease activity requiring high glucocorticoid dosages. However, contrasting data have emerged from studies focused on the association between osteonecrosis and disease activity. Fialho et al. reported a positive correlation between the development of osteonecrosis and the SLEDAI score (an integrated index of disease activity) ≥8 in the year preceding the clinical diagnosis of osteonecrosis [43]. On the contrary other studies did not find a correlation with disease activity [4, 5, 40] or severity [41].

Inconclusive results were yielded by analyzing the association of osteonecrosis with some typical features of SLE like vasculitis [4, 8], Raynaud’s phenomenon [4, 6, 9], antiphospholipid antibody positivity [5, 6, 8, 10, 40, 44], and with administration of antimalarial drugs [4, 11]. Many authors reported a higher frequency of Cushingoid body habitus among SLE patients who developed osteonecrosis [8, 45, 46].

Osteonecrosis is relatively uncommon in growing individuals but its incidence rapidly increases in adolescents up to the rate seen in adults [35]. This may be related to the growing proportion of fatty marrow with advancing age. Fatty marrow as compared with red marrow has less collateral flow and is then more vulnerable to ischemic injury whereas children appear to better tolerate ischemia because they have abundant vascularity due to the sinusoidal network in hematopoietic red marrow [47]. A higher blood supply of femur head in pediatric patients after corticosteroid administration was demonstrated by dynamic MRI evaluation [48].

Another study on the prevalence of MRI detected osteonecrosis was carried out in Japan by Nakamura et al. Osteonecrosis MRI features were found in 260 of 676 joints (38%) in 169 SLE patients on treatment with corticosteroids. The authors ranked their cohort according to age: pediatric (<15 years old), adolescent (15–20 years old), and adult (>20 years old) with a prevalence of necrosis of 6%, 49% and 41% of the joints, respectively. None of the patients younger than 14 years developed osteonecrosis. These results indicate that patient age at the time of corticosteroid therapy initiation is an independent risk factor for osteonecrosis in SLE [49]. In a similar study in recipients of kidney transplantation no osteonecrosis cases were observed in children younger than 10 years [50].

The presence of arthritis [4], renal involvement [11], and the prevalence of anti-DNA and of various anti-ENA antibodies [5] could not be identified as risk factors for osteonecrosis. No differences in lipid profile were observed between SLE patients with and without osteonecrosis [11, 43, 44]. In a number of studies the incidence of osteonecrosis was significantly associated with the extensive use of immune suppressants drugs [4, 5, 44].

The aforementioned studies on the prevalence/incidence of osteonecrosis in SLE cannot be easily compared for their differences regarding important factors, such as age, duration of disease, duration of followup, dose, type, and route of administration of glucocorticoids. The definition of osteonecrosis was also different. It ranged from “clinical osteonecrosis” (the diagnosis having been achieved for the appearance of symptoms), X-ray, and eventually MRI-detected disease. For the latter it is not yet clear to what proportion these patients will develop full clinical picture of the disease, particularly keeping into account that effective treatment able to prevent the worsening of the disease is still lacking. What remains well established in all studies is the crucial role played by corticosteroid therapy in SLE patients.

5. Relationship between Osteonecrosis Development and Type of Corticosteroid Treatment

The relationship between development of osteonecrosis and corticosteroid treatment has been extensively investigated. Important risk factors appear to be the cumulative dose even for treatment cycles [5, 7, 9], the peak daily dose [5, 8, 44], the mean daily dose [5, 46], and the duration of use of high doses [51]. The use of methylprednisolone pulses was reported to be associated with osteonecrosis [38, 45], but this has not been confirmed by others [5, 16].

In all aforementioned studies the diagnosis of osteonecrosis was clinical and supported by traditional X-ray.

The epidemiological scenario has completely changed when the presence of osteonecrosis was identified also in asymptomatic patients by MRI. The use of this technique changed substantially the epidemiology of osteonecrosis and provided also interesting and unexpected data regarding the natural history of osteonecrosis in SLE. For example, in one of these studies it was found that osteonecrosis may occur soon after the beginning of corticosteroid therapy; all lesions were present within five months (on average after 3.1 months), and no new cases were observed afterward! In this particular study the corticosteroid dose was not significantly associated with osteonecrosis [17].

These results are somewhat supported by another interesting study prospectively evaluating by repeated MRI 291 joints in 106 SLE patients without osteonecrosis after the initial corticosteroid treatment. During the long follow-up period (on average 13.6 years) incidental osteonecrosis was observed only in 6 bone segments. In all these cases the osteonecrosis developed after a SLE flare requiring the increase of corticosteroid dosage. No cases of osteonecrotic lesions were found in patients who received a low or medium corticosteroid dose, equivalent to <30 mg/day of prednisone. Thus, it appears that if a SLE patient does not develop osteonecrosis after an initial course of high steroid therapy he will rarely present the complication afterwards unless the dose of corticosteroid is considerably increased as a consequence of a disease flare [52].

A study was focused on the MRI evolution over 10 years in SLE patients who already suffered from a noncollapsed and asymptomatic osteonecrosis at the hips or knees (238 (44%) out of 537 joints). During the followup in about half of the lesions spontaneous reduction of necrotic areas was observed with complete regression in 9% of the cases. Progression of the osteonecrotic lesions occurred in 14% of the cases, invariably associated with an increase of corticosteroid dosage due to SLE recurrence [53].

6. Treatment

The treatment of osteonecrosis in SLE patients is similar to that of osteonecrosis due to other causes. The goal of the treatment of osteonecrotic lesions is to preserve joint integrity by preventing bone collapse.

When osteonecrosis involves less than 10% of the femoral head or less than 1/3 of the weight-bearing portion the outcome is usually favourable and surgical treatment is not required [1]; the conservative treatment includes analgesics and the use of devices to allow nonweight bearing; these measures are usually effective in alleviating pain.

In case of symptomatic lesions surgical treatment is usually required.

Core decompression technique was performed for the first time in 1962 in order to reduce bone marrow pressure and to improve perfusion of ischemic bone [54]. Mont et al. treated by core decompression 31 hips in 18 SLE patients; in 21 cases (68%) a subsequent total joint replacement was required; all these cases were in an advance stage of the disease. The authors concluded that an early detection of the lesion and a prompt treatment are crucial to obtain optimal results [55]. Core decompression is usually ineffective when osteonecrosis involves more than 25% of the femoral head or more than 2/3 of the weight-bearing portion [1]. Core decompression was successfully performed in cases of osteonecrosis of the knee and of the talus in the precollapsed stages [55, 56].

Concentrated autologous bone marrow aspirate transplantation following core decompression was successfully performed in 8 out 9 SLE cases with osteonecrosis of the femur head involving more than 2/3 of the weight-bearing portion; only the patient who showed an advanced stage lesion failed to obtain benefit and later required joint replacement. Non perioperative complications were observed [57].

Another option is free vascularised fibular grafting; this procedure was applied in 80 osteonecrotic lesions of the hip among 50 SLE patients who were followed at least for two years after the procedure, on average for 4.3 years; none of the cases required hip arthroplasty, suggesting that free vascularised fibular grafting may allow to maintain joint function [58].

Transtrochanteric anterior rotational osteotomy demonstrated to be effective in a long-term study, showing a hip survival rate of 73.7% after 25 years from the surgical approach [59].

A 19-year-old woman affected by SLE who developed bilateral femur osteonecrosis that affected more than 2/3 of the weight-bearing area was treated with extracorporeal shockwave under general anesthesia obtaining significant pain relief, hip functional amelioration, and reduction of bone edema [60]. Shockwave treatment may favour neovascularization through an increased release of angiogenic factors [61] and may enhance bone mass and bone strength as demonstrated in rabbits [62]. After this first favourable experience, 15 SLE patients with 26 hips affected by osteonecrosis were treated with extracorporeal shockwave; hip replacement was necessary in 12% of the cases. The outcome was similar to that observed in a group of non-SLE patients with osteonecrosis [63].

The outcome of hip arthroplasty in SLE-associated osteonecrosis is not different from that observed in other indications; an overall survival probability of 94.6% at 5 years and of 81.8% at 9 years was reported with minimal perioperative morbidity [64]. In 19 SLE patients who underwent 26 hip arthroplasty interventions, two early, nonrecurrent dislocations, and one low-grade prosthetic infection were described [65].

Less favourable results were obtained for knee arthroplasty in SLE patients with osteonecrosis; a good outcome was reported in 11 out of 25 cases. No differences were found when patients were stratified by amount of corticosteroid use, cemented versus cementless fixation, and SLE activity [66].

Alendronate 70 mg per week was tested in a randomized placebo controlled study in 40 patients affected by unilateral or bilateral nontraumatic osteonecrosis of the femoral head with a necrotic area larger than 30%. Only 2 out of 29 femoral heads collapsed in the group treated with alendronate in comparison with 19 out of 25 femoral heads in the control group. Joint replacement was necessary in 1 alendronate-treated patient as compared with 16 cases of the placebo group [67]. A prospective study evaluating the effectiveness of the contemporaneous administration in SLE patients of high corticosteroid dose with bisphosphonate should be planned in order to establish if this class of drugs may prevent the onset or may halt the progression of osteonecrotic lesions.

The preventive strategy for osteonecrosis development in SLE patients requiring high corticosteroid dose to control disease activity has been seldom studied. Sixty newly diagnosed SLE patients treated with ≥40 mg of prednisolone daily were alternatively assigned to two options, a warfarin group and a control group; warfarin was given together with the initiation of corticosteroid therapy. Silent and symptomatic osteonecrosis developed in 21% and 4.8% of the hips in the warfarin group, respectively, and in 33% and 14% of the hips in the control group, respectively. Despite the lack of a statistically significant difference, the observed results indicate that larger studies are warranted in order to verify the efficacy of anticoagulation therapy for preventing osteonecrosis at least in SLE patients [68].

According to the actual understanding of the pathophysiology of osteonecrosis, some preventing benefits might be expected from the treatment with lipid lowering agents, antiplatelet drugs, and antiresorptives. However, in a small study in SLE patients with disease flare requiring increased corticosteroid dosage, no beneficial effects were observed with the concomitant administration of statin, antiplatelet, and bisphosphonate [69].

7. Conclusion

Osteonecrosis frequently complicates the course of SLE, usually occurs soon after the initiation of corticosteroid therapy at high doses or, more rarely, after increasing the dosage for SLE flares. The complication may have a significant impact on functional ability and may require in some cases total joint replacement.

The presence of localized asymptomatic forms can be nowadays identified by MRI. By using this technique the incidence of osteonecrosis in SLE patients appears to be considerably higher than hitherto thought.

Recent MRI serial evaluation of hips and knees shed more light on the natural history of osteonecrosis, which does not progress if the dose of corticosteroid is maintained low and possibly thanks to promising preventive strategies, such as warfarin and bisphosphonates. However, at the moment the best documented preventive strategy is a judicious glucocorticoid use which is now possible by adopting steroid-sparing therapies, including the new biological agents.

References

  1. P. Lafforgue, “Pathophysiology and natural history of avascular necrosis of bone,” Joint Bone Spine, vol. 73, no. 5, pp. 500–507, 2006. View at: Publisher Site | Google Scholar
  2. M. Abu-Shakra, D. Buskila, and Y. Shoenfeld, “Osteonecrosis in patients with SLE,” Clinical Reviews in Allergy and Immunology, vol. 25, no. 1, pp. 13–23, 2003. View at: Publisher Site | Google Scholar
  3. N. Sugano, T. Atsumi, K. Ohzono, T. Kubo, T. Hotokebuchi, and K. Takaoka, “The 2001 revised criteria for diagnosis, classification, and staging of idiopathic osteonecrosis of the femoral head,” Journal of Orthopaedic Science, vol. 7, no. 5, pp. 601–605, 2002. View at: Publisher Site | Google Scholar
  4. D. D. Gladman, M. B. Urowitz, V. Chaudhry-Ahluwalia, D. C. Hallet, and R. J. Cook, “Predictive factors for symptomatic osteonecrosis in patients with systemic lupus erythematosus,” Journal of Rheumatology, vol. 28, no. 4, pp. 761–765, 2001. View at: Google Scholar
  5. C. C. Mok, C. S. Lau, and R. W. S. Wong, “Risk factors for avascular bone necrosis in systemic lupus erythematosus,” British Journal of Rheumatology, vol. 37, no. 8, pp. 895–900, 1998. View at: Google Scholar
  6. A. Rascu, K. Manger, H. G. Kraetsch, J. R. Kalden, and B. Manger, “Osteonecrosis in systemic lupus erythematosus, steroid-induced or a lupus-dependent manifestation?” Lupus, vol. 5, no. 4, pp. 323–327, 1996. View at: Google Scholar
  7. M. Abeles, J. D. Urman, and N. F. Rothfield, “Aseptic necrosis of bone in systemic lupus erythematosus. Relationship to corticosteroid therapy,” Archives of Internal Medicine, vol. 138, no. 5, pp. 750–754, 1978. View at: Publisher Site | Google Scholar
  8. M. A. Mont, C. J. Glueck, I. H. Pacheco, P. Wang, D. S. Hungerford, and M. Petri, “Risk factors for osteonecrosis in systemic lupus erythematosus,” Journal of Rheumatology, vol. 24, no. 4, pp. 654–662, 1997. View at: Google Scholar
  9. E. S. Weiner and M. Abeles, “Aseptic necrosis and glucocorticosteroids in systemic lupus erythematosus: a reevaluation,” Journal of Rheumatology, vol. 16, no. 5, pp. 604–608, 1989. View at: Google Scholar
  10. M. Y. Mok, V. T. Farewell, and D. A. Isenberg, “Risk factors for avascular necrosis of bone in patients with systemic lupus erythematosus: is there a role for antiphospholipid antibodies?” Annals of the Rheumatic Diseases, vol. 59, no. 6, pp. 462–467, 2000. View at: Publisher Site | Google Scholar
  11. P. Uea-Areewongsa, S. Chaiamnuay, P. Narongroeknawin, and P. Asavatanabodee, “Factors associated with osteonecrosis in Thai lupus patients: a case control study,” Journal of Clinical Rheumatology, vol. 15, no. 7, pp. 345–349, 2009. View at: Publisher Site | Google Scholar
  12. J. H. Klippel, L. H. Gerber, L. Pollak, and J. L. Decker, “Avascular necrosis in systemic lupus erythematosus. Silent symmetric osteonecroses,” American Journal of Medicine, vol. 67, no. 1, pp. 83–87, 1979. View at: Google Scholar
  13. A. A. Kalla, I. D. Learmonth, and P. Klemp, “Early treatment of avascular necrosis in systemic lupus erythematosus,” Annals of the Rheumatic Diseases, vol. 45, no. 8, pp. 649–652, 1986. View at: Google Scholar
  14. R. A. Asherson, F. Liote, B. Page et al., “Avascular necrosis of bone and antiphospholipid antibodies in systemic lupus erythematosus,” Journal of Rheumatology, vol. 20, no. 2, pp. 284–288, 1993. View at: Google Scholar
  15. L. Cozen and D. J. Wallace, “Avascular necrosis in systemic lupus erythematosus: clinical associations and a 47-year perspective,” American Journal of Orthopedics, vol. 27, no. 5, pp. 352–354, 1998. View at: Google Scholar
  16. D. D. Gladman, V. Chaudhry-Ahluwalia, D. Ibañez, E. Bogoch, and M. B. Urowitz, “Outcomes of symptomatic osteonecrosis in 95 patients with systemic lupus erythematosus,” Journal of Rheumatology, vol. 28, no. 10, pp. 2226–2229, 2001. View at: Google Scholar
  17. K. Oinuma, Y. Harada, Y. Nawata et al., “Osteonecrosis in patients with systemic lupus erythematosus develops very early after starting high dose corticosteroid treatment,” Annals of the Rheumatic Diseases, vol. 60, no. 12, pp. 1145–1148, 2001. View at: Publisher Site | Google Scholar
  18. L. G. Darlington, “Osteonecrosis at multiple sites in a patient with systemic lupus erythematosus,” Annals of the Rheumatic Diseases, vol. 44, no. 1, pp. 65–66, 1985. View at: Google Scholar
  19. S. N. Oh, W. H. Jee, S. M. Cho et al., “Osteonecrosis in patients with systemic lupus erythematosus: MR imaging and scintigraphic evaluation,” Clinical Imaging, vol. 28, no. 4, pp. 305–309, 2004. View at: Publisher Site | Google Scholar
  20. K. Nagasawa, H. Tsukamoto, Y. Tada et al., “Imaging study on the mode of development and changes in avascular necrosis of the femoral head in systemic lupus erythematosus: long-term observations,” British Journal of Rheumatology, vol. 33, no. 4, pp. 343–347, 1994. View at: Google Scholar
  21. M. A. Mont, M. G. Zywiel, D. R. Marker, M. S. McGrath, and R. E. Delanois, “The natural history of untreated asymptomatic osteonecrosis of the femoral head: a systematic literature review,” Journal of Bone and Joint Surgery A, vol. 92, no. 12, pp. 2165–2170, 2010. View at: Publisher Site | Google Scholar
  22. A. F. Mourão, M. Amaral, J. Caetano-Lopes, and D. Isenberg, “An analysis of joint replacement in patients with systemic lupus erythematosus,” Lupus, vol. 18, no. 14, pp. 1298–1302, 2009. View at: Google Scholar
  23. N. E. Lane, “Therapy Insight: osteoporosis and osteonecrosis in systemic lupus erythematosus,” Nature Clinical Practice Rheumatology, vol. 2, no. 10, pp. 562–569, 2006. View at: Publisher Site | Google Scholar
  24. J. Zwerina, S. Hayer, M. Tohidast-Akrad et al., “Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction,” Arthritis and Rheumatism, vol. 50, no. 1, pp. 277–290, 2004. View at: Publisher Site | Google Scholar
  25. S. S. Davies, A. V. Pontsler, G. K. Marathe et al., “Oxidized alkyl phospholipids are specific, high affinity peroxisome proliferator-activated receptor gamma ligands and agonists,” Journal of Biological Chemistry, vol. 276, no. 19, pp. 16015–16023, 2001. View at: Publisher Site | Google Scholar
  26. F. Parhami, Y. Tintut, W. G. Beamer, N. Gharavi, W. Goodman, and L. L. Demer, “Atherogenic high-fat diet reduces bone mineralization in mice,” Journal of Bone and Mineral Research, vol. 16, no. 1, pp. 182–188, 2001. View at: Google Scholar
  27. L. C. Jones, M. A. Mont, T. B. Le et al., “Procoagulants and osteonecrosis,” Journal of Rheumatology, vol. 30, no. 4, pp. 783–791, 2003. View at: Google Scholar
  28. C. J. Glueck, R. A. Freiberg, R. N. Fontaine, T. Tracy, and P. Wang, “Hypofibrinolysis, thrombophilia, osteonecrosis,” Clinical Orthopaedics and Related Research, no. 386, pp. 19–33, 2001. View at: Google Scholar
  29. A. Almeida and I. Roberts, “Bone involvement in sickle cell disease,” British Journal of Haematology, vol. 129, no. 4, pp. 482–490, 2005. View at: Publisher Site | Google Scholar
  30. J. Arlet, P. Ficat, G. Lartigue, and M. A. Tran, “Clinical research on intraosseous pressure in the upper femoral metaphysis and epiphysis in humans. Application to the diagnosis of ischemia and necrosis,” Revue du Rhumatisme et des Maladies Osteo-Articulaires, vol. 39, no. 11, pp. 717–723, 1972. View at: Google Scholar
  31. B. C. Vande Berg, J. Malghem, F. E. Lecouvet, J.-P. Devogelaer, B. Maldague, and F. A. Houssiau, “Fat conversion of femoral marrow in glucocorticoid-treated patients: a cross-sectional and longitudinal study with magnetic resonance imaging,” Arthritis and Rheumatism, vol. 42, no. 7, pp. 1405–1411, 1999. View at: Publisher Site | Google Scholar
  32. W. Fukushima, M. Fujioka, T. Kubo, A. Tamakoshi, M. Nagai, and Y. Hirota, “Nationwide epidemiologic survey of idiopathic osteonecrosis of the femoral head,” Clinical Orthopaedics and Related Research, vol. 468, no. 10, pp. 2715–2724, 2010. View at: Publisher Site | Google Scholar
  33. M. Sakaguchi, T. Tanaka, W. Fukushima, T. Kubo, and Y. Hirota, “Impact of oral corticosteroid use for idiopathic osteonecrosis of the femoral head: a nationwide multicenter case-control study in Japan,” Journal of Orthopaedic Science, vol. 15, no. 2, pp. 185–191, 2010. View at: Publisher Site | Google Scholar
  34. D. A. Stroh, D. M. Laporte, D. A. Marker, A. J. Johnson, and M. A. Mont, “Atraumatic osteonecrosis of the distal radius and ulna: case series and review,” Journal of Hand Surgery, vol. 37, no. 1, pp. 134–141, 2012. View at: Publisher Site | Google Scholar
  35. T. Shigemura, J. Nakamura, S. Kishida et al., “Incidence of osteonecrosis associated with corticosteroid therapy among different underlying diseases: prospective MRI study,” Rheumatology, vol. 50, no. 11, pp. 2023–2028, 2011. View at: Google Scholar
  36. R. S. Weinstein, “Glucocorticoids, osteocytes, and skeletal fragility: the role of bone vascularity,” Bone, vol. 46, no. 3, pp. 564–570, 2010. View at: Publisher Site | Google Scholar
  37. M. García-Carrasco, C. Mendoza-Pinto, R. O. Escárcega et al., “Osteoporosis in patients with systemic lupus erythematosus,” Israel Medical Association Journal, vol. 11, no. 8, pp. 486–491, 2009. View at: Google Scholar
  38. X. Y. Yang and D. H. Xu, “MDR1(ABCB1) gene polymorphisms associated with steroid-induced osteonecrosis of femoral head in systemic lupus erythematosus,” Pharmazie, vol. 62, no. 12, pp. 930–932, 2007. View at: Publisher Site | Google Scholar
  39. T. Asano, K. A. Takahashi, M. Fujioka et al., “ABCB1 C3435T and G2677T/A polymorphism decreased the risk for steroid-induced osteonecrosis of the femoral head after kidney transplantation,” Pharmacogenetics, vol. 13, no. 11, pp. 675–682, 2003. View at: Publisher Site | Google Scholar
  40. F. A. Houssiau, A. N'Zeusseu Toukap, G. Depresseux et al., “Magnetic resonance imaging-detected avascular osteonecrosis in systemic lupus erythematosus: lack of correlation with antiphospholipid antibodies,” British Journal of Rheumatology, vol. 37, no. 4, pp. 448–453, 1998. View at: Google Scholar
  41. R. Prasad, D. Ibanez, D. Gladman, and M. B. Urowitz, “The role of non-corticosteroid related factors in osteonecrosis (ON) in systemic lupus erythematosus: a nested case-control study of inception patients,” Lupus, vol. 16, no. 3, pp. 157–162, 2007. View at: Publisher Site | Google Scholar
  42. A. Zonana-Nacach, S. G. Barr, L. S. Magder et al., “Damage in systemic lupus erythematosus and its association with corticosteroids,” Arthritis and Rheumatism, vol. 43, no. 8, pp. 1801–1808, 2000. View at: Publisher Site | Google Scholar
  43. S. C. M. S. Fialho, E. Bonfá, L. F. Vitule et al., “Disease activity as a major risk factor for osteonecrosis in early systemic lupus erythematosus,” Lupus, vol. 16, no. 4, pp. 239–244, 2007. View at: Publisher Site | Google Scholar
  44. J. Calvo-Alén, G. McGwin, S. Toloza et al., “Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXIV. Cytotoxic treatment is an additional risk factor for the development of symptomatic osteonecrosis in lupus patients: results of a nested matched case-control study,” Annals of the Rheumatic Diseases, vol. 65, no. 6, pp. 785–790, 2006. View at: Publisher Site | Google Scholar
  45. L. Massardo, S. Jacobelli, M. Leissner, M. González, L. Villarroel, and S. Rivero, “High-dose intravenous methylprednisolone therapy associated with osteonecrosis in patients with systemic lupus erythematosus,” Lupus, vol. 1, no. 6, pp. 401–405, 1992. View at: Google Scholar
  46. T. M. Zizic, C. Marcoux, and D. S. Hungerford, “Corticosteroid therapy associated with ischemic necrosis of bone in systemic lupus erythematosus,” American Journal of Medicine, vol. 79, no. 5, pp. 596–604, 1985. View at: Google Scholar
  47. D. G. Mitchell, M. E. Steinberg, M. K. Dalinka, V. M. Rao, M. Fallon, and H. Y. Kressel, “Magnetic resonance imaging of the ischemic hip. Alterations within the osteonecrotic, viable, and reactive zones,” Clinical Orthopaedics and Related Research, no. 244, pp. 60–77, 1989. View at: Google Scholar
  48. J. Nakamura, Y. Miura, S. Ikenoue et al., “Blood supply of proximal femur during steroid therapy in SLE patients using dynamic MRI,” in Proceedings of the 77th Annual Meeting of the American Academy of Orthopaedic Surgeons, New Orleans, La, USA, March 2010. View at: Google Scholar
  49. J. Nakamura, T. Saisu, K. Yamashita, C. Suzuki, M. Kamegaya, and K. Takahashi, “Age at time of corticosteroid administration is a risk factor for osteonecrosis in pediatric patients with systemic lupus erythematosus: a prospective magnetic resonance imaging study,” Arthritis and Rheumatism, vol. 62, no. 2, pp. 609–615, 2010. View at: Publisher Site | Google Scholar
  50. P. Stern and H. G. Watts, “Osteonecrosis after renal transplantation in children,” Journal of Bone and Joint Surgery A, vol. 61, no. 6, pp. 851–856, 1979. View at: Google Scholar
  51. S. Migliaresi, U. Picillo, L. Ambrosone et al., “Avascular osteonecrosis in patients with SLE: relation to corticosteroid therapy and anticardiolipin antibodies,” Lupus, vol. 3, no. 1, pp. 37–41, 1994. View at: Google Scholar
  52. J. Nakamura, S. Ohtori, M. Sakamoto, A. Chuma, I. Abe, and K. Shimizu, “Development of new osteonecrosis in systemic lupus erythematosus patients in association with long-term corticosteroid therapy after disease recurrence,” Clinical and Experimental Rheumatology, vol. 28, no. 1, pp. 13–18, 2010. View at: Google Scholar
  53. J. Nakamura, Y. Harada, K. Oinuma, S. Iida, S. Kishida, and K. Takahashi, “Spontaneous repair of asymptomatic osteonecrosis associated with corticosteroid therapy in systemic lupus erythematosus: 10-year minimum follow-up with MRI,” Lupus, vol. 19, no. 11, pp. 1307–1314, 2010. View at: Publisher Site | Google Scholar
  54. R. P. Ficat, “Treatment of avascular necrosis of the femoral head,” The Hip, pp. 279–295, 1983. View at: Google Scholar
  55. M. A. Mont, A. C. Fairbank, M. Petri, and D. S. Hungerford, “Osteonecrosis in patients with systemic lupus erythematosus develops very early after starting high dose corticosteroid treatment,” Clinical Orthopaedics and Related Research, vol. 334, pp. 91–97, 1997. View at: Google Scholar
  56. R. E. Delanois, M. A. Mont, T. R. Yoon, M. Mizell, and D. S. Hungerford, “Atraumatic osteonecrosis of the talus,” Journal of Bone and Joint Surgery A, vol. 80, no. 4, pp. 529–536, 1998. View at: Google Scholar
  57. T. Yoshioka, H. Mishima, H. Akaogi, S. Sakai, M. Li, and N. Ochiai, “Concentrated autologous bone marrow aspirate transplantation treatment for corticosteroid-induced osteonecrosis of the femoral head in systemic lupus erythematosus,” International Orthopaedics, vol. 35, no. 6, pp. 823–829, 2010. View at: Publisher Site | Google Scholar
  58. Y. Sun, C. Q. Zhang, S. B. Chen, J. G. Sheng, D. X. Jin, and B. F. Zeng, “Treatment of femoral head osteonecrosis in patients with systemic lupus erythematosus by free vascularised fibular grafting,” Lupus, vol. 18, no. 12, pp. 1061–1065, 2009. View at: Publisher Site | Google Scholar
  59. G. Motomura, T. Yamamoto, K. Suenaga et al., “Long-term outcome of transtrochanteric anterior rotational osteotomy for osteonecrosis of the femoral head in patients with systemic lupus erythematosus,” Lupus, vol. 19, no. 7, pp. 860–865, 2010. View at: Publisher Site | Google Scholar
  60. P. C. Lin, C. J. Wang, K. D. Yang, F. S. Wang, J. Y. Ko, and C. C. Huang, “Extracorporeal shockwave treatment of osteonecrosis of the femoral head in systemic lupus erythematosis,” Journal of Arthroplasty, vol. 21, no. 6, pp. 911–915, 2006. View at: Publisher Site | Google Scholar
  61. C. J. Wang, F. S. Wang, K. D. Yang et al., “Shock wave therapy induces neovascularization at the tendon-bone junction. A study in rabbits,” Journal of Orthopaedic Research, vol. 21, no. 6, pp. 984–989, 2003. View at: Publisher Site | Google Scholar
  62. C. J. Wang, K. D. Yang, F. S. Wang, C. C. Hsu, and H. H. Chen, “Shock wave treatment shows dose-dependent enhancement of bone mass and bone strength after fracture of the femur,” Bone, vol. 34, no. 1, pp. 225–230, 2004. View at: Publisher Site | Google Scholar
  63. C. J. Wang, J. Y. Ko, Y. S. Chan et al., “Extracorporeal shockwave for hip necrosis in systemic lupus erythematosus,” Lupus, vol. 18, no. 12, pp. 1082–1086, 2009. View at: Publisher Site | Google Scholar
  64. M. H. Huo, E. A. Salvati, M. G. Browne, P. M. Pellicci, T. P. Sculco, and N. A. Johanson, “Primary total hip arthroplasty in systemic lupus erythematosus,” Journal of Arthroplasty, vol. 7, no. 1, pp. 51–56, 1992. View at: Publisher Site | Google Scholar
  65. P. Zangger, D. D. Gladman, M. B. Urowitz, and E. R. Bogoch, “Outcome of total hip replacement for avascular necrosis in systemic lupus erythematosus,” Journal of Rheumatology, vol. 27, no. 4, pp. 919–923, 2000. View at: Google Scholar
  66. M. A. Mont, T. H. Myers, K. A. Krackow, and D. S. Hungerford, “Total knee arthroplasty for corticosteroid associated avascular necrosis of the knee,” Clinical Orthopaedics and Related Research, no. 338, pp. 124–130, 1997. View at: Google Scholar
  67. K. A. Lai, W. J. Shen, C. Y. Yang, C. J. Shao, J. T. Hsu, and R. M. Lin, “The use of alendronate to prevent early collapse of the femoral head in patients with nontraumatic osteonecrosis: a randomized clinical study,” Journal of Bone and Joint Surgery A, vol. 87, no. 10, pp. 2155–2159, 2005. View at: Publisher Site | Google Scholar
  68. K. Nagasawa, Y. Tada, S. Koarada et al., “Prevention of steroid-induced osteonecrosis of femoral head in systemic lupus erythematosus by anti-coagulant,” Lupus, vol. 15, no. 6, pp. 354–357, 2006. View at: Publisher Site | Google Scholar
  69. F. Sekiya, K. Yamaji, K. Yang, H. Tsuda, and Y. Takasaki, “Investigation of occurrence of osteonecrosis of the femoral head after increasing corticosteroids in patients with recurring systemic lupus erythematosus,” Rheumatology International, vol. 30, no. 12, pp. 1587–1593, 2010. View at: Publisher Site | Google Scholar

Copyright © 2012 Paola Caramaschi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

9446 Views | 1356 Downloads | 15 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder